Lucetam pills 1200 mg 20 pcs
Condition: New product
992 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Piracetam
Release form
Pills
Composition
1 tablet, coated, contains: active substance: piracetam 1200 mg. Adjuvants: magnesium stearate, povidone K-30, macrogol 6000, dibutylsebactate, titanium dioxide (E171), talc, ethyl cellulose, hypromellose.
Pharmacological effect
Nootropic drug. It has an effect on the central nervous system in various ways: it modifies neurotransmission in the brain, improves the conditions that promote neuronal plasticity, improves microcirculation, affects the rheological characteristics of the blood and does not cause vasodilation. The use of piracetam in patients with cerebral dysfunction increases concentration and improves cognitive functions, which manifests significant changes in EEG (increased α and β activity, decreased δ activity). Contributes to the restoration of cognitive functions after effect of various disorders such as hypoxia, intoxication or electroconvulsive therapy. Reduces the duration of vestibular neuronitis. Piracetam inhibits the increased aggregation of activated platelets and, in the case of pathological rigidity of erythrocytes, improves their deformability and ability to filter.
Pharmacokinetics
AbsorptionAfter taking the drug inside piracetam quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability of the drug is about 100%. After a single dose of 2 g, Cmax is reached in the blood plasma after 30 minutes and is 40-60 μg / ml, after 2-8 hours in the cerebrospinal fluid. The distribution and metabolism of Vd is about 0.6 l / kg. Piracetam selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, in the cerebellum and basal nuclei. It does not bind to plasma proteins. Piracetam penetrates the BBB and placental barrier. Not metabolized in the body. Excretion of T1 / 2 from blood plasma is 4-5 h, T1 / 2 of cerebrospinal fluid - 8.5 h. It is excreted by the kidneys unchanged. Excretion by the kidneys is almost complete (> 95%) within 30 hours. The total clearance of piracetam in healthy volunteers is 86 ml / min. Pharmacokinetics in special clinical situations. With renal failure, T1 / 2 increases.
Indications
Symptomatic treatment of intellectual disorders in the absence of an established diagnosis of dementia; in order to reduce the manifestations of cortical myoclonia in piracetam-sensitive patients, both as monotherapy and as part of complex therapy (a trial course of treatment may be conducted to determine sensitivity to piracetam in a particular case).
Contraindications
- Hemorrhagic stroke. - End-stage renal failure (with creatinine clearance less than 20 ml / min). - Children under 1 year of age. - Pregnancy. - Lactation. - Hypersensitivity to piracetam or pyrrolidone derivatives, as well as other components of the drug.
Precautionary measures
Precautions should be prescribed the drug for violations of hemostasis, extensive surgery, severe bleeding, chronic renal failure (CC 20-80 ml / min).
Use during pregnancy and lactation
Adequate and strictly controlled clinical studies on the safety of the drug during pregnancy has not been conducted, so lucetam should not be used during pregnancy. Pyracetam penetrates the placental barrier, is excreted in breast milk. If necessary, the use of the drug during lactation breastfeeding should be discontinued.
Dosage and administration
Inside the drug is prescribed in a daily dose of 30-160 mg / kg, the multiplicity of reception - 2-4 times / day. Tablets Lucetam taken during a meal or fasting, squeezed liquid (water, juice). In symptomatic treatment of chronic psychoorganic syndrome, depending on the expression symptoms are prescribed 1.2-2.4 g / day, and during the first week - 4.8 g / day. In the treatment of the effects of a stroke, 4.8 g / day is prescribed. In alcohol withdrawal syndrome - 12 g / day. The maintenance dose is 2.4 g / day. For the treatment of dizziness and related balance disorders, 2.4-4.8 g / day is prescribed. In cortical myoclonia, treatment starts with a dose of 7.2 g / day, every 3-4 days the dose is increased by 4.8 g / day to achieve a maximum dose of 24 g / day. Treatment continues throughout the period of illness. Every 6 months, an attempt should be made to reduce the dose or discontinue the drug, gradually reducing the dose by 1.2 g every 2 days in order to prevent an attack.In the absence of an effect or a minor therapeutic effect, treatment is stopped. Children for the correction of reduced learning are prescribed orally at a dose of 3.2 g / day. Treatment continues throughout the school year. Patients with impaired liver function do not need to adjust the dosage regimen. Patients with impaired renal function require correction of the dosage regimen depending on creatinine response (CK). Degree of renal failure QC (ml / min) Dose Norma> 80 Usual dose Easy 50-79 2/3 usual dose in 2 - 3 doses Average 30-49 1/3 usual dose in 2 doses Heavy <30 1/6 usual dose, once Terminal stage - is contraindicated In elderly patients, the dose is corrected in the presence of renal failure and after-treatment. control of the functional state of the kidneys is necessary.
Side effects
On the part of the central nervous system: hyperkinesis, irritability, drowsiness, depression, asthenia, headache, dizziness, insomnia, mental agitation, anxiety, imbalance, tremor, ataxia, exacerbation of epilepsy, anxiety, hallucinations, confusion, increased libido. On the part of organs feelings: dizziness (vertigo). From the cardiovascular system: decrease or increase in blood pressure. From the digestive system: nausea, vomiting, diarrhea, abdominal pain, epigastric pain. From the side of metabolism and pita effects: weight gain. On the skin: dermatitis, pruritus, urticaria. On the immune system: hypersensitivity, anaphylactic reactions, angioedema.
Overdose
Piracetam is not toxic even in high doses. A single case of dyspeptic phenomena was observed in the form of diarrhea with blood and lower abdominal pain when taking the drug in a medicinal form. Oral solution in a daily dose of 75 g. Treatment: induction of vomiting, gastric lavage, symptomatic therapy, hemodialysis (efficiency 50-60%) . There is no specific antidote.
Interaction with other drugs
With simultaneous use with an extract of the thyroid gland (T3 + T4), irritability, disorientation and sleep disturbances are possible. There are no interactions with clonazepam, phenytoin, phenobarbital,Valproic Acid. Piracetam in high doses (9.6 g / day) increases the effectiveness of acenocoumarol in patients with venous thrombosis (there was a more pronounced decrease in the level of platelet aggregation, fibrinogen level, von Willebrand factors, blood and plasma viscosity compared to acenocoumarol). pharmacodynamics of piracetam under the influence of other drugs is low, because 90% of the drug is excreted unchanged in the urine. In vitro, piracetam does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 4A9 / 11 isoenzymes at 142, 426 and 1422 μg / ml. At a concentration of piracetam of 1422 mcg / ml, slight inhibition of CYP2A6 (21%) and 3A4 / 5 (11%) was observed. However, the level of Ki probably goes far beyond the concentration of 1422 μg / ml. Therefore, metabolic interaction with other drugs is unlikely. Receiving piracetam at a dose of 20 mg / day did not affect the Cmax and AUC of antiepileptic drugs in the blood serum (carbamazepine, phenytoin, phenobarbital, valproate) in epileptic patients receiving the drug at a constant dose. Joint administration with ethanol did not affect the level of serum piracetam concentration, the serum ethanol concentration did not change when taking piracetam at a dose of 1.6 g.
special instructions
Due to the effect of piracetam on platelet aggregation, the drug should be prescribed with caution to patients with hemorrhagic disorders, risk of bleeding (for example, in case of gastric ulcer), impaired hemostasis, patients taking anticoagulants and antiplatelet agents, including acetylsalicylic acid in low doses. When treating cortical myoclonia, abrupt interruption of treatment should be avoided, since this may cause the resumption of seizures. In case of long-term therapy in elderly patients, regular monitoring of renal function indicators is recommended, and dose adjustment is carried out, if necessary, depending on the results of the QC study. Penetrates through the filter membranes of hemodialysis machines. Effect on ability to drive vehicles and work with mechanisms treatment, care must be taken when driving and engaging in other potentially hazardous activities that require yuschimi high concentration and psychomotor speed reactions.